Table 1.
Participant demographic characteristics
| Characteristic | Total N | Values |
|---|---|---|
| Maternal age (y), mean (SD) | 131 | 31.2 (6.6) |
| Gravidity, median (IQR) | 131 | 2 (1–3) |
| Parity, median (IQR) | 131 | 1 (0–2) |
| BMI (kg/m2), mean (SD) | 109 | 31.3 (7.4) |
| Race, n (%) | 131 | |
| Other | 52 (39.7) | |
| White | 25 (19.1) | |
| Unknown or not reported | 25 (19.1) | |
| Asian | 18 (13.7) | |
| Black | 11 (8.4) | |
| >1 race | 0 (0) | |
| Ethnicity, n (%) | 131 | |
| Hispanic or Latino | 58 (44.3) | |
| Not Hispanic or Latino | 69 (52.7) | |
| Unknown or not reported | 4 (3.1) | |
| Maternal comorbidities, n (%) | ||
| Chronic hypertension | 131 | 8 (6.1) |
| Gestational hypertension | 131 | 21 (16.0) |
| Preeclampsia without severe features | 131 | 7 (5.3) |
| Preeclampsia with severe features | 131 | 15 (11.5) |
| Pregestational diabetes mellitus | 131 | 2 (1.5) |
| Gestational diabetes mellitus | 131 | 20 (15.3) |
| BMI>30 kg/m2 | 131 | 55 (49.6) |
| Asthma | 111 | 20 (15.3) |
| Other preexisting pulmonary conditiona | 131 | 4 (3.1) |
| Chronic kidney disease | 131 | 1 (0.8) |
| Substance use | 130 | 3 (2.3) |
| IVF pregnancy | 131 | 7 (5.3) |
| Anticoagulation in antepartum period, n (%) | 67 | |
| Aspirin | 18 (26.9) | |
| Lovenox | 2 (3.0) | |
| Both | 2 (3.0) | |
| None | 45 (67.2) | |
| Abnormal genetic screening, n (%) | 131 | 10 (7.6) |
| Fetal and pregnancy complications, n (%) | 131 | |
| Multiple pregnancy | 8 (6.1) | |
| Fetal growth restriction | 13 (9.9) | |
| Clinical chorioamnionitis | 12 (9.2) | |
| Placental abruption | 2 (1.5) | |
| Umbilical cord or placental anomaliesb | 5 (3.8) | |
| Trimester when COVID-19 was diagnosed, n (%) | 131 | |
| First | 10 (7.6) | |
| Second | 31 (23.7) | |
| Third | 90 (68.7) | |
| COVID-19 severity, n (%) | 131 | |
| Asymptomatic | 30 (22.9) | |
| Mild | 78 (59.5) | |
| Moderate | 10 (7.6) | |
| Severe | 4 (3.1) | |
| Critical | 9 (6.9) | |
| Interval between date of COVID-19 diagnosis and due date (d), median (IQR) | 129 | 54 (20–112) |
| Interval between first COVID-19 symptoms and due date (d), median (IQR) | 80 | 72 (39–129) |
| Composite maternal morbidity, n (%)c | 131 | |
| At the time of delivery | 28 (21.2) | |
| At the time of COVID-19 related admission | 71 (53.8) |
BMI, body mass index; IQR, interquartile range; IVF, in vitro fertilization; SD, standard deviation.
a
Included history of pulmonary embolism (n=1), sleep apnea (n=1), Hodgkin lymphoma (n=1), and latent tuberculosis (n=1)
b
Included single umbilical artery (n=1), velamentous cord insertion, marginal cord insertion (n=1), vasa previa, placenta previa (n=1), and placenta accreta (n=1)
c
Refer to Supplemental Table 1 for more details
Corbetta-Rastelli. COVID-19 placental pathology. Am J Obstet Gynecol MFM 2023.